CASE REPORT

Extraordinarily long-inactive solitary fibrous tumor transformed to produce big insulin-like growth factor-2, leading to hypoglycemia and rapid liposarcoma growth: a case report

Keizo Kaneko1, Shojiro Sawada1, Chiihiro Satake1, Keiichi Kondo1, Tomohito Izumi1, Mamiko Tanaka1, Junta Imai1, Tetsuya Yamada1, Hiroki Katsushima2, Fumiyoshi Fujishima2 and Hideki Katagiri1*

Abstract

Background: A high-molecular-weight form of insulin-like growth factor-2 (IGF-2), known as “big” IGF-2, is occasionally produced by various tumor types, leading to hypoglycemia. Although solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm, it has been estimated that 4–6% of SFT patients develop hypoglycemia due to circulating big IGF-2. The mean time elapsed from tumor detection until the onset of hypoglycemia is reportedly less than one year (8.5 ± 1.9 months).

Case presentation: A 68-year-old man was hospitalized for exacerbation of recurring hypoglycemic episodes. He had been diagnosed with an SFT 17 years before the onset of hypoglycemia, and the SFT had already been very large at that time. The tumor, which was non-resectable and refractory to chemotherapies, had slowly increased in size since the initial diagnosis. Half a year before the hypoglycemic episodes manifested, another tumor, adjacent to the left kidney, was newly identified. Fluorodeoxyglucose positron emission tomography-computed tomography scanning, revealed the left peri-renal tumor to show much higher fluorodeoxyglucose uptake than the preexisting SFT, suggesting that it was unlikely to be a metastasis from the SFT. Abundant serum big IGF-2 was detected by western immunoblot analysis, indicating it to be the cause of the hypoglycemia. Since the 17 years between SFT detection and the onset of IGF-2-induced hypoglycemia was an extremely long period as compared with those in previous reports, we initially suspected that the new, peri-renal tumor had produced big IGF-2, but transcatheter arterial embolization of its feeding arteries did not suppress hypoglycemia. Notably, by measuring the tumor volume doubling time, the peri-renal tumor growth was shown to be markedly accelerated in parallel with exacerbation of the hypoglycemia. The patient died of heart failure 21 months after the onset of hypoglycemia. Unexpectedly, autopsy revealed that big IGF-2 had been produced only by the preexisting SFT, not the peri-renal tumor, and that the peri-renal tumor was a dedifferentiated liposarcoma.

(Continued on next page)
Conclusions: We should keep in mind that even a long-inactive SFT can undergo transformation to produce big IGF-2, which then acts on both insulin and IGF-1 receptors, possibly leading to both hypoglycemia and the development/growth of another tumor, respectively.

Keywords: Solitary fibrous tumor, Insulin-like growth factor-2, Hypoglycemia, Tumor growth, Case report

Background
A high-molecular-weight form of insulin-like growth factor-2 (IGF-2), known as “big” IGF-2, is occasionally produced in various tumor types regardless of whether the origin is mesenchymal or epithelial, and can lead to hypoglycemia through insulin receptor (IR) signaling [1, 2]. Solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm, the natural course of which tends to be indolent. It has been estimated that 4–6% of SFT patients develop hypoglycemia due to circulating big IGF-2 [3], and the mean time elapsed from tumor detection until the onset of big IGF-2-induced hypoglycemia is reportedly 8.5 ± 1.9 months [1]. The single most effective therapy for the hypoglycemia is a complete surgical resection of the SFT. However, this is not feasible in cases whose tumors are already massive and invasive and/or show metastasis at diagnosis.

The IGF/type1 IGF receptor (IGF-1R) signaling system is reportedly associated with tumor cell proliferation, survival and metastasis [4]. There is, however, a paucity of literature demonstrating whether big IGF-2 exerts the tumor growth effect in an endocrine manner.

We encountered a case with SFT, who, 17 years after detection of the SFT, experienced both recurring episodes of hypoglycemia and the development/growth of another novel tumor, with high circulating big IGF-2 levels.

Case presentation
A 68-year-old man was hospitalized for exacerbation of recurring hypoglycemic episodes 18 months after the onset of these episode. He had been diagnosed with an abdominal SFT 17 years before the onset of hypoglycemia, and the SFT had already been very large at that time. The tumor was non-resectable, refractory to chemotherapies and had slowly increased in size, reaching volume of 2750 cm³, as measured using ITK-SNAP software [5], 8 years after the initial diagnosis.

Half a year before the hypoglycemic episodes manifested, another tumor, adjacent to the left kidney, had been newly identified. Fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography–computed tomography (PET-CT) scanning, performed 15 months after the onset of the hypoglycemic episodes, revealed much higher ¹⁸F-FDG uptake (standardized uptake value (SUV) max: 29) in the left peri-renal tumor than in the original tumor (SUVmax: 6.6) (Fig. 1a-b). Therefore, we considered that the peri-renal tumor was unlikely to be a metastasis from the SFT, although approximately 26 and 45% of SFT cases reportedly develop metastasis during 5- and 10-year follow-up periods, respectively [6].

His hypoglycemia generally manifested in the early morning or between meals. He took no glucose-lowering agents. The fasting plasma insulin level (0.2 μU/mL), compared to the plasma glucose concentration (48 mg/dL), was well suppressed (Table 1) and no pancreatic tumors were detected on detailed CT scans, likely excluding a diagnosis of insulinoma. As shown in Table 1, serum levels of counter regulatory hormones, such as adrenaline, cortisol and growth hormone, were not suppressed. The serum IGF-1 level was within the normal range. All serum liver enzyme levels were also within their normal ranges. During the current hospitalization, IGF-2 western immunoblot analysis of the patient’s serum showed a broad band between 11 and 18 kDa, showing a large amount of big IGF-2 (Fig. 1c). Its intensity was 15.6 times higher than that in a serum of a healthy subject (analyzed by ImageJ, NIH). These findings collectively indicated that big IGF-2 production was the cause of the hypoglycemia. Overnight continuous glucose infusion was started to prevent fasting hypoglycemia, following light snacks before bed, which had started a few months prior to hospital admission (Fig. 2). We considered the possibility that the newly-identified peri-renal tumor was responsible for the production of big IGF-2 and performed transcatheter arterial embolization of the arteries feeding the peri-renal tumor. However, the embolization exerted no preventive effects against hypoglycemia. Both the SFT and the peri-renal tumor continued to grow, reaching volumes of 10,000 cm³ and 438 cm³, respectively at 20 months after the onset of hypoglycemia (Fig. 2). The patient developed worsening lower limb edema due to enlargement of the preexisting SFT and his general condition deteriorated. Twenty-one months after the onset of the hypoglycemic episodes, he died of heart failure.

Contrary to our expectation, western immunoblot analysis of tumor extracts obtained from his autopsy specimens showed that big IGF-2 had been produced only by the preexisting SFT, not by the peri-renal tumor (Fig.
In addition, histological findings revealed the SFT to be composed of proliferative spindle cells with a component of collagen fibers (Fig. 3a). The tumor cells were immunohistochemically positive for CD34 (Fig. 3b), bcl2 (Fig. 3c) and STAT6 (Fig. 3d), typical immunohistochemical markers of SFT. On the other hand, the peri-renal tumor was morphologically composed of two components: a lesion comprised of proliferating mature adipocytes with fibrous tissues (well-differentiated liposarcoma) (Fig. 3e) and a lesion
comprised of proliferative spindle cell areas with no specific differentiation, regarded as an undifferentiated pleomorphic sarcoma (Fig. 3f). Other than the endothelial cells, nearly all components were CD34-negative (Fig. 3g). Taking these observations together, we diagnosed the peri-renal tumor as a dedifferentiated liposarcoma, but not a metastasis from the SFT. Ki67-positive cell ratios of the SFT and the liposarcoma were less than 1% and approximately 15%, respectively, reflecting the rapid growth of the peri-renal liposarcoma (Fig. 3h-i).

Discussion and conclusions
Mature IGF-2 is 7.5 kDa peptide and exerts its effects by binding to the IR or IGF-1R. In certain clinical settings, big IGF-2 (11–18 kDa) is abundantly produced by abnormal processing of an IGF-2 precursor in tumors. Big IGF-2 mainly forms a binary complex with IGF binding proteins (IGFBP), rather than the normal 150 kDa ternary complex with IGFBP-3 and an acid labile subunit, and thus can easily pass through the endothelium and gain access to the IR of parenchymal cells, leading to refractory hypoglycemia [7].

Table 1 Laboratory data

| Parameter                      | Unit           | Normal range          |
|--------------------------------|----------------|-----------------------|
| Glucose                        | mg/dL (mmol/L) | 68–109 (3.78–6.06)   |
| Insulin                        | μU/mL          | 0–18.7                |
| Glucagon                       | pg/mL          | 71–174                |
| Adrenaline                     | ng/mL          | 0–0.1                 |
| Noradrenaline                  | ng/mL          | 0.1–4.5               |
| Cortisol                       | μg/dL          | 6.2–19.4              |
| ACTH                           | pg/mL          | 4.4–48                |
| GH                             | ng/mL          | 0–2.47                |
| Insulin-like growth factor-1   | ng/mL          | 70–229                |
| Asparate aminotransferase      | IU/L           | 8–38                  |
| Alanine aminotransferase       | IU/L           | 4–43                  |
| γ-glutamyl transferase         | IU/L           | 10–47                 |

ACTH adrenocorticotropic hormone, GH growth hormone

Fig. 2 Timeline of the patient’s clinical course, including the development/growth of the tumors and hypoglycemia treatments. Tumor volumes (cm³) on CT scans were measured using ITK-SNAP software at four time points. TVDTs (days) were calculated as follows: TVDT = (T_y – T_x) × log 2 / (log V_y – log V_x). T_y – T_x indicates the time interval between the two measurements and V_x and V_y represent the tumor volumes at T_x and T_y, respectively. T_0: time of the onset of the hypoglycemic episode, T_1: 6 months after the onset of the hypoglycemic episode, T_2: 15 months after the onset of the hypoglycemic episode, T_3: 20 months after the onset of the hypoglycemic episode, TAE: transcatheter arterial embolization, PET-CT: positron emission tomography-computed tomography, TVDT: tumor volume doubling time, TV: tumor volume
According to previous reviews, tumor types causing hypoglycemia vary from mesenchymal (e.g., leiomyoma and SFT) to epithelial (e.g., hepatocellular carcinoma) in origin [1, 2]. Among the mesenchymal tumors, the tumor type with the most prominent IGF-2 expression, in terms of both frequency and magnitude, was SFT [8]. Notably, the mean time elapsed from tumor detection until the onset of IGF-2-induced hypoglycemia is reportedly 8.5 ± 1.9 MONTHS [1]. Although the preexisting SFT was very large, the extraordinarily long period of 17 YEARS in this case prompted us to initially suspect that the peri-renal tumor was responsible for the big-IGF2 production. Contrary to our expectation, however, it was the preexisting SFT, despite its prolonged inactivity, that had produced IGF-2 and caused the patient’s recurring hypoglycemic episodes. On the other hand, the peri-renal tumor, metabolically active and rapidly growing, did not produce big IGF-2 and was found to be a dedifferentiated liposarcoma.

The IGF-1R signaling system is reportedly associated with tumor cell proliferation, survival and metastasis and has thus been extensively investigated as a target for cancer therapy [4]. In liposarcoma cases, the IGF-1R is highly expressed, and blockade of IGF signaling is reportedly one of the therapeutic targets for this disease [9, 10]. Therefore, the large amount of circulating big IGF-2 observed in our patient may have contributed to very rapid dedifferentiated liposarcoma growth with active metabolism, in addition to causing hypoglycemia. To test this hypothesis, we employed the tumor volume doubling time (TVDT) to examine alterations in the tumor growth rate after the onset of the hypoglycemic episodes (Fig. 2). TVDT, as originally described by Schwartz [11], was often calculated using tumor diameters, resulting in overestimation of the volume. The tumor volume in our case was thus measured using the ITK-SNAP software, a more accurate method based on contour segmentation of CT images [5]. Interestingly, there was a dramatical reduction in TVDT of the liposarcoma, from 2010 to 72 days, indicating a remarkably increased rate of tumor growth, associated with worsening hypoglycemia, which finally required overnight continuous glucose infusion therapy (Fig. 2). The detailed time course of the serum big IGF-2 level would further verify the importance of IGF-2 in the development/growth of the peri-renal liposarcoma.

This case exemplifies a rare but clinically significant phenomenon of biologic transformation of an SFT to secrete big IGF-2 after an extraordinary long period of dormancy, resulting in clinicopathological manifestations and possibly increased growth of another tumor.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12902-020-00624-2.

Additional file 1. Uncropped western immunoblot image related to Fig. 1c.
Additional file 2. Procedure of protein extraction and immunoblot analysis and information of antibodies for immunoblotting and immunohistochemistry.

Abbreviations
IGF: Insulin-like growth factor; SFT: Solitary fibrous tumor; FDG: Fluorodeoxyglucose; PET-CT: Positron emission tomography-computed tomography; IR: Insulin receptor; IGF-1R: Type1 IGF receptor; SUV: Standardized uptake value; IGFBP: IGF binding proteins; TVDT: Tumor volume doubling time

Acknowledgements
We would like to thank Dr. Akira Arai, Kousei Sendai Clinic, Sendai, for giving us useful advice regarding interpretation of the PET-CT scans.

Authors’ contributions
K. K.1 and H. K.1 contributed to relevant discussions and wrote, reviewed and edited the manuscript. S. S., J. I., and T. Y. contributed to overall relevant discussions and reviewed the manuscript. K. K.1, C. S., T. I. K. K.2 and M. T. took responsibility for patient management and participated in discussions and review of the manuscript. H. K.2 and F. F contributed the histological diagnosis of the tumors. H. K.1 is the guarantor of this work and, as such, had full access to all of the data and takes responsibility for the integrity of the data as well as the accuracy of the data analysis. All authors have read and approved the manuscript and ensured that this was the case in which they were involved.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethics approval was deemed to be unnecessary by the Ethics Committee Tohoku University Graduate School of Medicine since this case report is not a clinical study according to the ethical guidelines.

Consent for publication
Written informed consent for publication of their clinical details and/or clinical images was obtained from the relative of the patient. Consent form can be made available to the Editor if requested.

Competing interests
None to declare.

Author details
1Department of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi 980-8575, Japan. 2Division of Hematopathology, Tohoku University Hospital, Sendai, Aoba-ku, Japan.

Received: 15 May 2020 Accepted: 13 September 2020
Published online: 29 September 2020

References
1. Fukuda I, Hishida N, Iikawa Y, Yasumoto K, Murakami Y, Sata A, Moita J, Kurimoto M, Okubo Y, Takano K. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Hormone IGF Res. 2006;16(4):211–6.
2. Khwaja A, Johnson-Rabett B, Bantle J, Moheet A. Hypoglycemia mediated by paraneoplastic production of insulin like growth factor-2 from a malignant renal solitary fibrous tumor - clinical case and literature review. BMC Endocr Disord. 2014;14:49.
3. England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura: A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989;13(8):640–58.
4. Livingstone C. IGF2 and cancer. Endocr Relat Cancer. 2013;20(6):R21–39.
5. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, Gerig G. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31(3):1116–28.
6. Beckwith H, Yee D. Mini review: Were the IGF Signaling Inhibitors All Bad? Mol Endocrinol (Baltimore, Md). 2015;29(11):1549–57.
7. Dynkevich Y, Rother KL, Whitford I, Qureshi S, Galvani S, Saulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798–826.
8. Steigen SE, Schaeffer DF, West RB, Nielsen TO. Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Modern Pathol. 2009;22(7):914–21.
9. May CD, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Sannaa GAA, Bhalla AD, Wang Wl, et al. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017;18(10):816–26.
10. Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, Lopez-Terrada DH, et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma: deregulation of targetable tyrosine kinase receptors. Lab Invest. 2011;91(3):392–403.
11. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272–94.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.